Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 12:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 102 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Infection or Inflammation Clear all
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia

NCT03604705
View directory record Official record
Conditions
Candidemia
Interventions
APX001
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Davis, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 23, 2026, 12:24 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia

NCT01701219
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia, Methicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia
Interventions
Ceftaroline fosamil
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
27
States / cities
Birmingham, Alabama • Sacramento, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Jul 23, 2026, 12:24 PM EDT
Recruiting Not applicable Interventional

The Role of Circadian Clock Proteins in Innate and Adaptive Immunity

NCT03482245
View directory record Official record
Conditions
Pneumonia, Necrotizing Soft Tissue Infection, Intraabdominal Infections, Infection Joint
Interventions
Blue Light
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jul 23, 2026, 12:24 PM EDT
Terminated Not applicable Interventional

Loop Drainage: Effectiveness in Treating Cutaneous Abscesses

NCT02697279
View directory record Official record
Conditions
Abscess of Skin and/or Subcutaneous Tissue
Interventions
Traditional Incision and Drainage., Loop drainage
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Jul 23, 2026, 12:24 PM EDT
Completed Not applicable Interventional

Comparative Effectiveness of Readmission Reduction Interventions for Individuals with Sepsis or Pneumonia

NCT04829188
View directory record Official record
Conditions
Sepsis, Pneumonia, Lower Resp Tract Infection, Covid19
Interventions
Structured Telephone Support (STS), Low-intensity Remote Patient Monitoring (RPM-Low), High-intensity Remote Patient Monitoring (RPM-High), Standard Response Team, Enhanced Response Team
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older
Enrollment
1,288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Jul 23, 2026, 12:24 PM EDT
Not listed Phase 2 Interventional

Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections

NCT00057369
View directory record Official record
Conditions
Bacteremia
Interventions
dalbavancin
Drug
Lead sponsor
Vicuron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 12:24 PM EDT
Not listed No phase listed Observational

Symphony IL-6 Study in Patients at Risk of Severe Sepsis

NCT05665153
View directory record Official record
Conditions
Severe Sepsis
Interventions
Not listed
Lead sponsor
Bluejay Diagnostics, Inc.
Industry
Eligibility
22 Years and older
Enrollment
200 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Jul 23, 2026, 12:24 PM EDT
Completed Phase 4 Interventional

Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas

NCT00295178
View directory record Official record
Conditions
Cellulitis
Interventions
Daptomycin, Vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Jul 23, 2026, 12:24 PM EDT
Completed Phase 3 Interventional

An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections

NCT00001810
View directory record Official record
Conditions
Aspergillosis, Candidiasis, Fungemia, Mycoses
Interventions
Voriconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 12:24 PM EDT
Not listed No phase listed Observational

POC SPLA2-IIA as a Biomarker for Sepsis and Septic Shock

NCT03953404
View directory record Official record
Conditions
Sepsis
Interventions
SPLA2-IIA
Diagnostic Test
Lead sponsor
St. Luke's Hospital, Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
450 participants
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Jul 23, 2026, 12:24 PM EDT
Completed Early Phase 1 Interventional

Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS

NCT02452216
View directory record Official record
Conditions
Brain Injury, Central Nervous System Degenerative Disorder, Central Nervous System Infectious Disorder, Central Nervous System Vascular Malformation, Hemorrhagic Cerebrovascular Accident, Ischemic Cerebrovascular Accident, Primary Brain Neoplasm, Brain Cancer, Brain Tumors
Interventions
Ferumoxytol, Tissue Analysis, Magnetic Resonance Imaging
Drug · Other · Procedure
Lead sponsor
Michael Iv
Other
Eligibility
2 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Jul 23, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

NCT01321879
View directory record Official record
Conditions
Infection, Bacteremia
Interventions
Telavancin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Jul 23, 2026, 12:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults

NCT02015091
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 23, 2026, 12:24 PM EDT
Completed Phase 3 Interventional

A Randomized Clinical Trial to Prevent Recurrent CA-MRSA Infection

NCT00560599
View directory record Official record
Conditions
Methicillin Resistant Staphylococcus Aureus Skin Infections
Interventions
mupirocin and chlorhexidine, household cleaning and disinfection, mupirocin, chlorhexidine, & household cleaning/disinfection
Drug · Behavioral
Lead sponsor
loren g miller
Other
Eligibility
1 Month and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Anaheim, California • Bellflower, California • Harbor City, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Jul 23, 2026, 12:24 PM EDT
Completed No phase listed Observational Results available

Home Away From Home - Medical Outcomes

NCT02774850
View directory record Official record
Conditions
Acute Myeloid Leukemia, Neutropenia, Bacteremia
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 19 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
17
States / cities
Little Rock, Arkansas • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2019 · Synced Jul 23, 2026, 12:24 PM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women

NCT02210689
View directory record Official record
Conditions
BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include, Vaginal Discharge Color, Odor, and Consistency, Vulvovaginal Itching and Irritation (Subjective) Absent, Mild, Moderate, or Severe, Vulvovaginal Inflammation (Objective) Absent, Mild, Moderate, or Severe
Interventions
clindamycin phosphate vaginal cream 2%, placebo
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
15
States / cities
Birmingham, Alabama • La Mesa, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Jul 23, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites

NCT02436876
View directory record Official record
Conditions
Bacterial Infection
Interventions
MBN-101, Placebo
Drug · Other
Lead sponsor
Microbion Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Jul 23, 2026, 12:24 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Pulmonary and Inflammatory Responses Following Exposure to a Low Concentration of Ozone or Clean Air at Rest

NCT06943989
View directory record Official record
Conditions
Lung Inflammation, Experimental Lung Inflammation
Interventions
Ozone Exposure, Clean air (0.0 ppm ozone)
Other
Lead sponsor
Environmental Protection Agency (EPA)
Federal
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Jul 23, 2026, 12:24 PM EDT
Recruiting Phase 3 Interventional

PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation

NCT05699174
View directory record Official record
Conditions
Infections, Infected Wound, Nonunion of Fracture, Injury Leg, Amputation, Internal Fixation; Complications, Infection or Inflammation, Fracture, Lower Extremity Fracture, Antibiotic Side Effect
Interventions
Standard of Care PO (oral) antibiotics, Standard of Care Intravenous (IV) antibiotics
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
13
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Minneapolis, Minnesota + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 23, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

NCT02734862
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis
Interventions
CD101, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Davis, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Jul 23, 2026, 12:24 PM EDT
Not listed Not applicable Interventional

Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial

NCT02258984
View directory record Official record
Conditions
Severe Sepsis, Acute Heart Failure
Interventions
Mespere Venus 1000 Non-Invasive CVP System
Device
Lead sponsor
Mespere Lifesciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced Jul 23, 2026, 12:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

To Compare Different Soft Tissue Grafts at the Time of Lateral Ridge Augmentation Procedure.

NCT03774888
View directory record Official record
Conditions
Bone Graft; Complications, Infection or Inflammation, Ridge Deficency, Dental Implant
Interventions
Connective tissue graft at time of bone graft, Acellular Demal Matrix at time of bone graft, No soft tissue grafting at time of bone graft
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Jul 23, 2026, 12:24 PM EDT
Completed Not applicable Interventional

Non-Invasive Cardiac Output Monitor (NICOM) for Goal-directed Fluid Resuscitation for Inpatients With Hypotension and/or Septic Shock

NCT05630716
View directory record Official record
Conditions
Sepsis, Hypotension, Septic Shock
Interventions
NICOM
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Jul 23, 2026, 12:24 PM EDT
Enrolling by invitation No phase listed Observational

Evaluation and Long-Term Follow-up of Patients With Inflammatory Disorders

NCT00001351
View directory record Official record
Conditions
Inflammation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 23, 2026, 12:24 PM EDT